Nov 9, 2017   SOURCE: PR NewsWire

DRG Publishes New Type 1 Diabetes Content; Forecasted Displacement Of Branded Insulins With Biosimilars, Increase In Treatment Options With Fiasp And SGLT Inhibitor Adjuncts To Insulin.

BURLINGTON, Mass., Nov. 9, 2017 /PRNewswire/ -- Decision Resources Group forecasts the type 1 diabetes (T1D) G7 market to reach $3.9 billion by 2026, with substantial sales growth forecast across the three sub-populations studied. We anticipate several drug launches to capture share from established players, while evolving treatment practice and further newcomers are forecast to expand the market. Market tailwinds include life-long treatment with high-cost agents, polypharmacy, and a rising global T1D incidence.

Other key findings from the Disease Landscape & Forecast report entitled Type 1 Diabetes:

    --  The G7 launch of Fiasp, the launch of several biosimilar insulins, and
        the approval of the SGLT inhibitor class for the treatment of T1D are
        set to change the T1D treatment landscape through 2026, with
        displacement of Lantus, NovoLog, and Humalog by their respective
        biosimilars, and the partial cannibalization of NovoLog by Novo
        Nordisk's own ultra rapid-acting Fiasp.
    --  SGLT inhibitors will provide patients with another treatment option to
        manage the disease and will likely be used as an adjunct to insulins.
        Despite later line use, we project the class to command sizeable market
        share by 2026.
    --  Advancements in insulin pump devices through 2026 are set to drive the
        use of rapid-acting insulins and negate the need for routine use of
        long-acting insulins in these patients.
    --  Top unmet needs in T1D include the existence of extreme blood glucose
        troughs and peaks that are inherent to T1D, poor adherence to injected
        treatment, and the unpredictability of response to insulin treatment
        seen among some patients.

Comments from Decision Resources Group Analyst Kerri Brown:

    --  "Our T1D forecast reflects DRG's analysis and consideration of recent
        and future events. Through 2026, sales of insulins will continue to
        dominate the T1D market, while sales potential of SGLT inhibitors will
        be limited by their adjunctive role, and by the absolute requirement for
        insulin in T1D. Major drivers of market expansion will be life-long
        treatment with exogenous insulin injections, increasing polypharmacy
        with the launch of SGLT inhibitors for T1D, and the rising incidence of
        type 1 diabetes in the G7."
    --  "In T1D adults and children, insulin pump use is markedly higher in the
        United States than the remainder of the G7 countries. These pumps
        support the increased use of rapid-acting insulins, and negate the need
        for long-acting insulins. Advances in fully automated, "artificial
        pancreas" systems are expected to increase the percentage of adults and
        children using pumps, and further support the sales potential of
        rapid-acting insulins."

For more information on purchasing this report, please visit our website.

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Stephanie Cooper
212-414-7570
scooper@dresources.com

View original content with multimedia:http://www.prnewswire.com/news-releases/drg-publishes-new-type-1-diabetes-content-forecasted-displacement-of-branded-insulins-with-biosimilars-increase-in-treatment-options-with-fiasp-and-sglt-inhibitor-adjuncts-to-insulin-300551905.html

SOURCE Decision Resources Group